NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy

NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced it has raised $67 million in a funding round led by Accelmed Partners with participation from an unnamed strategic investor, Revelation Partners, Soleus Capital, and returning investors KCK Group and OrbiMed Advisors. The financing includes $33 million of new equity capital and $34 million from convertible debt provided by current investors from a prior funding round. An additional $27 million in committed capital is available in a second tranche. The funds will be used to accelerate commercial growth and to pursue expanded indications for the RNS® System, the company’s innovative technology for refractory focal epilepsy.